Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VALORY PAVLIK and RACHELLE DOODY.
VALORY PAVLIK
Connection Strength
2.426
RACHELLE DOODY
  1. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. J Alzheimers Dis. 2013; 34(2):449-56.
    View in: PubMed
    Score: 0.457
  2. Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment. Alzheimers Res Ther. 2011 Oct 17; 3(5):30.
    View in: PubMed
    Score: 0.420
  3. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). Neuroepidemiology. 2005; 24(1-2):42-50.
    View in: PubMed
    Score: 0.258
  4. Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. J Alzheimers Dis. 2022; 85(1):31-45.
    View in: PubMed
    Score: 0.213
  5. Different Cognitive Profiles Are Associated with Progression Rate and Age at Death in Probable Alzheimer's Disease. J Alzheimers Dis. 2021; 80(2):735-747.
    View in: PubMed
    Score: 0.199
  6. Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. Alzheimers Dement (Amst). 2015 Dec; 1(4):464-71.
    View in: PubMed
    Score: 0.138
  7. Factors that influence survival in a probable Alzheimer disease cohort. Alzheimers Res Ther. 2012 May 15; 4(3):16.
    View in: PubMed
    Score: 0.109
  8. Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample. Dement Geriatr Cogn Disord. 2010; 30(6):486-91.
    View in: PubMed
    Score: 0.100
  9. Predicting progression of Alzheimer's disease. Alzheimers Res Ther. 2010 02 23; 2(1):2.
    View in: PubMed
    Score: 0.094
  10. Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. Dement Geriatr Cogn Disord. 2009; 28(6):536-40.
    View in: PubMed
    Score: 0.092
  11. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009 Oct 21; 1(2):7.
    View in: PubMed
    Score: 0.092
  12. Is functional decline necessary for a diagnosis of Alzheimer's disease? Dement Geriatr Cogn Disord. 2007; 24(5):375-9.
    View in: PubMed
    Score: 0.079
  13. Influence of premorbid IQ and education on progression of Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 22(4):367-77.
    View in: PubMed
    Score: 0.074
  14. Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies LRRC4C, LHX5-AS1 and nominates ancestry-specific loci PTPRK , GRB14 , and KIAA0825 as novel risk loci for Alzheimer's disease: the Alzheimer's Disease Genetics Consortium. medRxiv. 2023 Jul 08.
    View in: PubMed
    Score: 0.059
  15. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):259-69.
    View in: PubMed
    Score: 0.025
  16. Survival among patients with dementia from a large multi-ethnic population. Alzheimer Dis Assoc Disord. 2005 Oct-Dec; 19(4):178-83.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.